Breaking Finance News

RXi Pharmaceuticals Announces Positive Data from Phase 1 Study

RHi Pharmaceuticals (OTC: RXII) said in a press release Friday, that phase 1 studies of its experimental compounds RXI-109 and sd-rxRNA showed that the drug was well-tolerated at all doses and positive outcomes for patients.

The drugs are indicated for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery.

The study, which involved three cohorts of healthy individuals, was administered by making small incisions in their abdomens. Over a two week period they were treated with RX-109 on one side of their abdomen and a placebo on the other side. Participants were monitored for 84 days where administrators of the study looked for local and systemic side effects.

Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals said,

“We are very pleased with the outcome of this second Phase 1 study.  These results show that multiple intradermal injections of RXI‑109 are well tolerated with minimal and mild side effects. He added that, “The work done in the last year has confirmed that our proprietary self-delivering RNAi technology (sd-rxRNA) reduces CTGF mRNA in humans in line with its mechanism of action. Indeed, results from this second study demonstrate that mRNA for CTGF in the incisions is reduced in a dose-dependent manner by RXI‑109 as compared to placebo. Our first Phase 1 study had already shown that a single dose of the drug lowered the actual protein content for CTGF also in a dose-dependent manner. With this exciting outcome, we are ready to embark on Phase 2 development in patients with hypertrophic scars and keloids.”

RXi Pharmaceuticals is an over-the-counter stock currently trading for $0.194 cents per share on average volume of 839,803 shares.

[stock-tools exchange="OTC" symbol="RXII" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.